Q-omics provides the consensus-scored ZNF765 profile across patient tissues and cancer cell-line models. ZNF765 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ZNF765 is differentially expressed in 12, with the highest sampling consensus in BLCA. Additionally, ZNF765 RNA expression shows 21,185 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight MESO, BLCA, and KIRP as cancer lineages where ZNF765 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF765 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF765 survival associations across molecular data types. ZNF765 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF765 RNA expression–survival associations across cancer types. High ZNF765 expression shows unfavorable associations in MESO, LIHC, LGG, CESC and LUSC, but favorable associations in KIRC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for ZNF765 RNA expression.
This table summarizes ZNF765 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF765. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF765 shows lower tumor expression in THCA and higher tumor expression in BLCA, COAD, HNSC, STAD and LIHC. The BLCA box plot shows higher ZNF765 RNA expression in tumor versus normal tissue (log2 FC = +0.697, t-test p < 0.001).
This table shows molecular features associated with ZNF765 in patient tissues and cancer cell lines. In patient samples, ZNF765 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF765 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
